GPR55 and Stroke: Spleen size was measured at 3 days post-stroke in mice, and indeed, tMCAO led to a 32.6% reduction in spleen size, whereas treatment with ML-193, a specific GPR55 antagonist, diminished these effects by almost 93% (Figure 2).